IgA nephropathy, or Berger's disease is a condition brought on by immunoglobulin A (IgA) buildup in the kidneys' filtering units, or glomeruli. Over time, inflammation brought on by this accumulation may impede renal function. Although the precise etiology is uncertain, infections or genetic factors may be involved. Swelling, proteinuria, and blood in the urine are common symptoms. It can develop into renal failure if treatment is not received. Symptom management, blood pressure control, and perhaps immunosuppressive medicine are all part of the treatment. The rising number of cases is anticipated to impact the pipeline landscape for IgA nephropathy emerging drugs positively.
Report Coverage
The IgA Nephropathy Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into IgA nephropathy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for IgA nephropathy. The IgA nephropathy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The IgA nephropathy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with IgA nephropathy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to IgA Nephropathy.
IgA Nephropathy Pipeline Outlook
When immunoglobulin A (IgA) is inappropriately deposited in the glomeruli, it triggers an inflammatory response that results in IgA nephropathy. IgA and other proteins produce immune complexes that activate complement and attract inflammatory cells, causing damage to kidney tissue. Reduced filtration, glomerular damage, and the development of chronic kidney disease are the outcomes of this. Repeated inflammation over time can cause kidney failure, fibrosis, and scarring.
IgA Nephropathy therapeutics include telitacicept, atrasentan, among others. The use of monoclonal antibodies to treat IgA nephropathy is being investigated. To lessen inflammation and stop additional kidney injury, these antibodies target particular immunological pathways, such as those involving B cells or the complement system. Monoclonal antibody treatments, such as those that target complement or CD20, are being researched to help individuals with IgA nephropathy. Further, the rising focus on the development of IgA Nephropathy emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
IgA Nephropathy Epidemiology
IgA nephropathy is thought to affect 2.5 out of every 100,000 people worldwide, with higher rates seen in East Asia, where it may be the cause of up to 40% of kidney biopsies. Due to variations in diagnosis procedures and population composition, the prevalence is lower in North America (10%) and Europe (20–30%). The male-to-female ratio ranges from 2:1 to 6:1, with males being the condition's primary victims.
IgA Nephropathy – Drug Pipeline Therapeutic Assessment
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for IgA nephropathy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of IgA nephropathy drug candidates.
By Phase
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook